Lupposofi@macesari Interesting, to say the least. Fine, if geriatricians educate themselves about the neurological and pharmacological intricacies of AD (which begins maybe two decades before any symptoms), but very many memory patients meet a geriatrician way too late. I haven't met one thus far, and was a guinea-pig in aducanumab-research for 4 years (got it 10 mg/kg). From my own experience and what I have studied during the journey, I concur with the minimal clinical advantage and the heavy burden of monthly infusions. But it is quite another question, who should lead the patience care at MCI-level and before, where MAB's can still make a difference.